Valneva (VALN) Expected to Announce Earnings on Wednesday

Valneva (NASDAQ:VALN) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $55.64 million for the quarter.

Valneva Stock Up 2.3 %

Shares of VALN opened at $7.06 on Wednesday. The company has a market capitalization of $573.70 million, a P/E ratio of -54.31 and a beta of 1.93. Valneva has a one year low of $3.62 and a one year high of $9.50. The business’s 50 day simple moving average is $5.97 and its 200-day simple moving average is $5.61. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Valneva in a research note on Friday, February 28th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.